Caxton Advantage Life Sciences Fund

Vivus, Inc., established in 1991 and based in Campbell, California, is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies. Its primary product, Qsymia, is a prescription weight management treatment for obese and overweight patients with weight-related health issues. Vivus also offers Pancreaze for exocrine pancreatic insufficiency and Stendra for erectile dysfunction. The company's pipeline includes Qsymia for additional indications and VI-0106 for pulmonary arterial hypertension. Vivus collaborates with several pharmaceutical companies for product development and commercialization.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, specifically targeting antidote-controlled treatments. Founded in 2001 and headquartered in Durham, North Carolina, the company is known for its innovative approach to antithrombotic therapies, including its lead product, REG1, which is designed for patients experiencing acute coronary syndrome undergoing coronary revascularization procedures. Regado's research emphasizes the development of therapeutic aptamers paired with active control agents, aiming to address both arterial and venous thrombosis effectively.

Gemin X Pharmaceuticals is focused on the discovery, development, and commercialization of innovative cancer therapeutics aimed at improving patient outcomes. The company’s research centers on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070, also known as obatoclax. This small molecule is designed to selectively trigger programmed cell death, or apoptosis, and may also promote autophagy in cancer cells. Obatoclax has demonstrated encouraging results in preclinical and early clinical studies and is currently undergoing Phase 2 clinical trials, both as a standalone treatment and in combination therapies. In addition to obatoclax, Gemin X is developing GMX1777, an inhibitor of NAD+ synthesis, among other oncology products, providing patients with potential relief from various cancer conditions. The company holds patent protection for obatoclax until 2025.

Gemin X Pharmaceuticals is focused on the discovery, development, and commercialization of innovative cancer therapeutics aimed at improving patient outcomes. The company’s research centers on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070, also known as obatoclax. This small molecule is designed to selectively trigger programmed cell death, or apoptosis, and may also promote autophagy in cancer cells. Obatoclax has demonstrated encouraging results in preclinical and early clinical studies and is currently undergoing Phase 2 clinical trials, both as a standalone treatment and in combination therapies. In addition to obatoclax, Gemin X is developing GMX1777, an inhibitor of NAD+ synthesis, among other oncology products, providing patients with potential relief from various cancer conditions. The company holds patent protection for obatoclax until 2025.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, specifically targeting antidote-controlled treatments. Founded in 2001 and headquartered in Durham, North Carolina, the company is known for its innovative approach to antithrombotic therapies, including its lead product, REG1, which is designed for patients experiencing acute coronary syndrome undergoing coronary revascularization procedures. Regado's research emphasizes the development of therapeutic aptamers paired with active control agents, aiming to address both arterial and venous thrombosis effectively.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate, vecabrutinib, is a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK) currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. Additionally, Sunesis is advancing SNS-510, which is in preclinical studies for various tumor types, alongside partnered programs such as TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer quinolone derivative. The company has established collaborations, including an agreement with Biogen Idec MA, Inc. for small molecule BTK inhibitors and a licensing agreement with Takeda Pharmaceutical Company Limited for preclinical PDK1 inhibitors. Founded in 1998 and headquartered in South San Francisco, California, Sunesis Pharmaceuticals is committed to innovative approaches in the ongoing fight against cancer.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for serious diseases, particularly those associated with inflammation, including cardiovascular and autoimmune conditions. Founded in 2004 and headquartered in Hayward, California, the company is advancing several product candidates. Its notable projects include Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy currently in Phase III clinical trials for exocrine pancreatic insufficiency, and Blisibimod, which is undergoing Phase II trials for B-cell mediated autoimmune diseases such as IgA nephropathy. Anthera also develops varespladib methyl and varespladib sodium, both of which are in various stages of clinical trials for acute coronary syndrome and sickle cell disease, respectively. The company has established license agreements with major pharmaceutical firms, including Amgen and Eli Lilly, to enhance its development and commercialization efforts.

Corthera Inc., formerly known as BAS Medical, is a biopharmaceutical company focused on acquiring, developing, and commercializing therapies for acute care illnesses. The company's primary product candidate, relaxin, is derived from a naturally occurring polypeptide hormone and is currently undergoing evaluation in a global phase 2/3 clinical trial aimed at treating acute decompensated heart failure. Corthera holds worldwide rights for the development and commercialization of relaxin, positioning itself as a key player in addressing critical health challenges in the acute care sector.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, specifically targeting antidote-controlled treatments. Founded in 2001 and headquartered in Durham, North Carolina, the company is known for its innovative approach to antithrombotic therapies, including its lead product, REG1, which is designed for patients experiencing acute coronary syndrome undergoing coronary revascularization procedures. Regado's research emphasizes the development of therapeutic aptamers paired with active control agents, aiming to address both arterial and venous thrombosis effectively.